Global Erdosteine Market Size worth $150mn by 2025

Erdosteine Market size is set to surpass USD 150 million by 2025; according to a new research report by Global Market Insights, Inc.

Increasing demand for mucus regulating medicines owing to rise in air contaminants such as toxic gases, pollen, dust, organic material, emissions from vehicles and factories will boost the market for active pharmaceutical ingredient erdosteine. Contaminates in air cause inflammation of the larynx & pharynx thus heightening the production of phlegm. The erdosteine based medicines market share will increase as they are used to reduce the viscosity and sticky nature of mucus, making it easier to cough.


Request Sample Buy NowInquiry Before Buying


Change in consumer perceptions towards safety of medicines with factors such as clinical efficacy and low side effects will stimulate erdosteine market growth. It exhibits low side effects and has been given the designation of orphan drug by FDA.

Erdosteine Market

Get more details on this report - Request Free Sample PDF

Erdosteine market demand from nasopharyngitis application may witness significant gains at around 5.5% by 2025. Increasing nasopharyngitis or common cold cases due to the rising  allergy and weak immune system will boost the market for erdosteine based syrups and tablets. It is widely used in the pharmaceutical sector to reduce inflammation in the nasal passage.

Excessive smoking habits increases respiratory diseases risk such as asthma & bronchitis which exhibit the symptoms of cough, sore throat, stuffy nose, and congestion.

Browse key industry insights spread across 180 pages with 148 market data tables and 46 figures & charts from the report, “Erdosteine Market Size By Application (Bronchitis, Chronic Obstructive Pulmonary Disease, Nasopharyngitis), By End-Use (Pharmaceutical, Contract Manufacturing Companies, Research Institute), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025” in detail along with the table of contents:


U.S. erdosteine active pharmaceutical ingredient (API) market demand from contract manufacturing companies (CMOs) may witness significant gains at over 6.5% during the forecast period. Rise in consumer consciousness toward customized medicines and stringent government regulations on pharmaceutical products will stimulate market growth. Changing perceptions toward reduced costs and flexibility in manufacturing will boost the market share.

Italy erdosteine market demand may expect consumption at over 35 tons during the predicted timeframe. Increase in elderly population and change in environmental conditions will boost the market for erdosteine based cough syrups and cold medicines. . Increased prevalence of respiratory problems such as nasopharyngitis owing to cold temperature and weakened immune systems will stimulate regional market growth. Moreover, increasing importance owing to medical research and technological innovation in this sector may contribute towards the regional industry growth.

China erdosteine market demand may register significant gains at over 7% by the end of forecast period. Increasing cases of respiratory problems such as laryngopharyngitis and chronic sinusitis owing to rise in pollutions & contaminants like pollen, oxides, and harmful gasses will boost the industry demand. Rising cases of bronchitis in India, China, and South Korea due to an increase in air contaminants such as carbon mono oxide will stimulate the market share.

Taj Pharmaceuticals, Delta Finochem, Recipharm AB, Alitair Pharmaceuticals, Hanmi Pharmaceuticals, and Hikma Pharmaceuticals are key market players operating in erdosteine market. Companies are focusing to expand their business by investing in biochemical & clinical research to widen product portfolio and expand regional reach.

Inquiry Before BuyingRequest Sample

Erdosteine market research report includes in-depth coverage of the industry, with estimates & forecast in terms of volume in Tons and revenue in USD from 2014 to 2025, for the following segments:

By Application

  • Bronchitis
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Nasopharyngitis
  • Others

By End Use

  • Pharmaceutical
  • Contract manufacturing companies (CMOs)
  • Research Institutes

The above information is provided on a regional and country basis for the following:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Brazil
  • MEA
    • Saudi Arabia
    • UAE
    • South Africa



Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X